The benefits of decades of epigenetics research have made their way into medical practice. Appia has been investigating a family of proprietary compounds that appear to reverse the abnormal epigenetic modification patterns found in certain malignant cancer cells such as lymphoma and neurodegenerative diseases such as Alzheimer’s Disease.

Appia’s lead cancer candidate, YF2, is a unique and orally bioavailable histone acetyltransferase (HAT) activator that exhibits efficacy in pre-clinical models of B-cell Lymphoma and is poised for clinical development.

Appia’s lead neurological candidate, RA013915, is a unique and orally bioavailable HAT activator has shown efficacy in four different mouse models of Alzheimer’s disease and related dementia.

There are no approved drugs or drugs at clinical trial stage with YF2’s and RA013915’s unique profiles of molecular recognition, pharmacological properties and safety. Therefore, YF2 and RA013915 have the potential to become new therapeutics against lymphoma and Alzheimer’s disease, respectively.

  • OUR TEAM IS INVESTIGATING A FAMILY OF PROPRIETARY COMPOUNDS
    THAT REVERSES ABNORMAL EPIGENETIC MODIFICATIONS FOUND IN CERTAIN CANCER CELLS AS WELL AS CELLS UNDERGOING NEURODEGENERATIVE PROCESSES.